Skip to main content

Exact Sciences, Mayo Expand Agreement to Include GI Cancers and Diseases

NEW YORK (GenomeWeb News) – Exact Sciences today announced it has expanded its collaboration with Mayo Clinic to include all gastrointestinal cancers and diseases, as well as new cancer screening applications of stool- and blood-based testing.

Exact will still have exclusive rights to commercialize products resulting from the new deal, which builds on a 2009 agreement between it and Mayo.

As part of the new agreement, Exact will make upfront, milestone, and royalty payments of an undisclosed amount to Mayo. It also will continue to fund the collaborative work of David Ahlquist, who developed the technology which formed the basis of the original 2009 agreement between the partners.

The collaboration between Exact and Mayo has resulted in the Cologuard biomarker panel for colorectal cancer that is currently in clinical trials and that Exact plans to commercialize after clearance from the US Food and Drug Administration. Exact has previously said that it expects to file for FDA clearance of the test later this year, with a clinical module submitted early in the first quarter of 2013.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.